Steward Partners Investment Advisory’s Lifecore Biomedical LFCR Stock Holding History

Steward Partners Investment Advisory’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$128K	Buy	34,277 +62	+0.2%	+$428	﹤0.01%	2246
2025 Q4	$280K	Buy	34,215 +326	+1%	+$2.41K	﹤0.01%	1749
2025 Q3	$249K	Buy	33,889 +1,128	+3%	+$8.54K	﹤0.01%	1751
2025 Q2	$266K	Buy	32,761 +2,528	+8%	+$17K	﹤0.01%	1614
2025 Q1	$213K	Buy	30,233 +3,049	+11%	+$18.9K	﹤0.01%	1618
2024 Q4	$202K	Buy	27,184 +10,320	+61%	+$65.9K	﹤0.01%	1608
2024 Q3	$83.1K	Buy	16,864 +9,088	+117%	+$47.5K	﹤0.01%	1974
2024 Q2	$39.9K	Buy	7,776 +3,535	+83%	+$20.9K	﹤0.01%	2212
2024 Q1	$22.5K	Buy	4,241 +2,177	+105%	+$15.6K	﹤0.01%	2473
2023 Q4	$12.8K	Buy	2,064 +1,234	+149%	+$8.57K	﹤0.01%	2605
2023 Q3	$6.26K	Buy	+830	New	+$7.59K	﹤0.01%	2749
2019 Q4	–	Sell	-1,000	Closed	-$10K	–	2674
2019 Q3	$10K	Hold	1,000	–	–	﹤0.01%	1989
2019 Q2	$9K	Buy	+1,000	New	+$10.1K	﹤0.01%	2029
2018 Q4	–	Sell	-1,000	Closed	-$14K	–	1538
2018 Q3	$14K	Buy	+1,000	New	+$13.8K	﹤0.01%	1730

Other funds holding LFCR

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Steward Partners Investment Advisory's LFCR Position: Q1 2026 in Review

Steward Partners Investment Advisory increased its Lifecore Biomedical (LFCR) stake by 0.18% in Q1 2026, buying an estimated $428 and bringing the position to 34,277 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #2246.

Steward Partners Investment Advisory first reported a position in LFCR in Q3 2018 and has held it in 14 quarters since. The position peaked at $280K in Q4 2025. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

Steward Partners Investment Advisory held 34,277 shares of Lifecore Biomedical worth $128K as of Q1 2026.
Steward Partners Investment Advisory bought 62 Lifecore Biomedical shares in Q1 2026, an estimated $428.
Lifecore Biomedical made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #2246 holding.
Steward Partners Investment Advisory first reported a position in Lifecore Biomedical in Q3 2018 and has held it in 14 quarters since.
Steward Partners Investment Advisory's Lifecore Biomedical position peaked at $280K in Q4 2025.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.